MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

Abstract

Aim: Neoadjuvant chemotherapy may represent a shift in the treatment of locally advanced colon cancer. The angiogenic couple has-microRNA-126 (miRNA-126) and epidermal growth factor-like domain 7 (EGFL7) are transcribed from the same gene and regulates all aspects of angiogenesis and may influence the ability of tumor cells to disseminate. The aim was to analyze the relationship between miRNA-126 and EGFL7 and disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy.

Methods: This study included 71 patients from a phase II study all planned for three cycles of capecitabine and oxaliplatin before surgery. Blood was sampled at baseline and right before and after the operation. Circulating miRNA-126 was analysed by RT-qPCR and a quantitative immunoassay was used for the analyses of EGFL7.

Results: The rates of 5-year disease-free survival (DFS) and overall survival (OS) were 80% and 85%, respectively. The level of circulating miRNA-126 before the operation predicts recurrence, P = 0.035. In patients with values below and above the median the recurrence rate was 31% and 4%, respectively. Similar results applied to EGFL7. A combined estimate identified a subgroup of patients (25 of 71) with no recurrence and a 5-year DFS and OS rate of 100%, respectively.

Conclusion: MicroRNA-126 and EGFL7 are predictors for disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy and may assist in selection of adjuvant chemotherapy.

Keywords

Chemotherapy / colon cancer / epidermal growth factor-like domain 7 / microRNA-126

References

[1] Andre T,Navarro M,Hickish T.Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial..J Clin Oncol2009;27:3109-16

[2] Foxtrot Collaborative GroupFeasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial..Lancet Oncol2012;13:1152-60 PMCID:PMC3488188

[3] Jakobsen A,Fischer A,Jorgensen JC.Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial..Acta Oncol2015;54:1747-53

[4] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[5] Carmeliet P.Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases..Nat Rev Drug Discov2011;10:417-27

[6] Sun Y,Zhang F,Guo Y.miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7..Biochem Biophys Res Commun2010;391:1483-9

[7] Saito Y,Chihara Y,Chuang JC.Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells..Biochem Biophys Res Commun2009;379:726-31

[8] Hu MH,Wang XM,Zhang GX.MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression..Oncotarget2016;7:66922-34 PMCID:PMC5341847

[9] Gong C,Li G,Liu ZS.Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma..Oncotarget2017;8:52527-42 PMCID:PMC5581048

[10] Fish JE,Morton SU,Yeh RF.miR-126 regulates angiogenic signaling and vascular integrity..Dev Cell2008;15:272-84 PMCID:PMC2604134

[11] Wang S,Johnson BA,McAnally J.The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis..Dev Cell2008;15:261-71 PMCID:PMC2685763

[12] Parker LH,Jin SW,Beis D.The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation..Nature2004;428:754-8

[13] Nikolic I,Bicker F,Braun H.EGFL7 ligates alphavbeta3 integrin to enhance vessel formation..Blood2013;121:3041-50

[14] Hansen TF,Lindebjerg J.The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer..BMC Cancer2012;12:83 PMCID:PMC3311029

[15] Hansen TF,Sorensen FB,Jakobsen A.Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer..Mol Cancer Ther2014;13:2238-45

[16] Hansen TF,Morgenthaler S,Lindebjerg J.The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort..J Transl Med2014;12:254 PMCID:PMC4174250

[17] Hansen TF,Jakobsen A.Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study..J Transl Med2015;13:10 PMCID:PMC4302134

[18] McShane LM,Sauerbrei W,Gion M.REporting recommendations for tumour MARKer prognostic studies (REMARK)..Br J Cancer2005;93:387-91 PMCID:PMC2361579

[19] Hansen TF,Heegaard NH,Jakobsen A.Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer..Br J Cancer2015;112:624-9 PMCID:PMC4333496

[20] Schmittgen TD.Analyzing real-time PCR data by the comparative C(T) method..Nat Protoc2008;3:1101-8

[21] Li XM,Zhang J.Down-regulation of miR-126 expression in colorectal cancer and its clinical significance..Med Oncol2011;28:1054-7

[22] Li N,Huang S,Li X.MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway..Mol Cell Biochem2013;380:107-19

[23] Ebrahimi F,Wahab R,Smith RA.Deregulation of miR-126 expression in colorectal cancer pathogenesis and its clinical significance..Exp Cell Res2015;339:333-41

[24] Liu Y,Feng X,Yang J.Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer..Genes Chromosomes Cancer2014;53:358-65

[25] Jorgensen S,Moller S.Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes..Methods2010;52:375-81

[26] Nielsen BS,Fog JU,Christensen IJ.High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patietns..Clin Exp Metastasis2011;28:27-38 PMCID:PMC2998639

[27] Guo C,Beard L,Markowitz SD.The noncoding RNA, miR- 126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers..Genes Chromosomes Cancer2008;47:939-46 PMCID:PMC2739997

[28] Zhu N,Xie H,Chen H.Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGF-A and PIK3R2..Mol Cell Biochem2011;351:157-64

[29] Liu Y,Feng X,Quan X.MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signalling pathways..Int J Oncol2014;44:203-10

[30] Zhou Y,Liu YL,Wang H.Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signalling pathways..PLoS One2013;8:e81203 PMCID:PMC3843680

[31] Hara T,Subramanian M,Ou O.Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells..Oncotarget2014;5:7635-50 PMCID:PMC4202150

[32] Dong Y,Guan H,Zhou T.Prognostic significance of miR-126 in various cancers: a meta-analysis..Onco Targets Ther2016;9:2547-55 PMCID:PMC4853159

[33] Yan J,Zhang Y,Zhou X.Potential role of mircroRNA-126 in the diagnosis of cancers. A systematic review and meta-analysis..Medicine2016;95:e4644 PMCID:PMC5008569

[34] Santulli G.MicroRNAs and Endothelial (Dys) Function..J Cell Physiol2016;231:1638-44 PMCID:PMC4871250